Page 24 - Read Online

Page 10 of 10 Lambert et al. J Transl Genet Genom 2018;2:11. I https://doi.org/10.20517/jtgg.2018.11

Nat Immunol 2011;12:239-46.
29. McKenna LB, Schug J, Vourekas A, McKenna JB, Bramswig NC, Friedman JR, Kaestner KH. MicroRNAs control intestinal epithelial dif-
ferentiation, architecture, and barrier function. Gastroenterology 2010;139:1654-64.e1.
30. Nakato G, Hase K, Sato T, Kimura S, Sakakibara S, Sugiyama M, Obata Y, Hanazato M, Iwanaga T, Ohno H. Epithelium-intrinsic microR-
NAs contribute to mucosal immune homeostasis by promoting M-cell maturation. PLoS One 2016;11:e0150379.
31. Lu TX, Lim EJ, Wen T, Plassard AJ, Hogan SP, Martin LJ, Aronow BJ, Rothenberg ME. MiR-375 is downregulated in epithelial cells after
IL-13 stimulation and regulates an IL-13-induced epithelial transcriptome. Mucosal Immunol 2012;5:388-96.
32. Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME.
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J
Allergy Clin Immunol 2012;129:1064-75.e9.
33. Zahm AM, Menard-Katcher C, Benitez AJ, Tsoucas DM, Le Guen CL, Hand NJ, Friedman JR. Pediatric eosinophilic esophagitis is associ-
ated with changes in esophageal microRNAs. Am J Physiol Gastrointest Liver Physiol 2014;307:G803-12.
34. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015;12:697.
35. Azouz NP, Ynga-Durand MA, Caldwell JM, Jain A, Rochman M, Fischesser DM, Ray LM, Bedard MC, Mingler MK, Forney C, Eil-
erman M, Kuhl JT, He H, Biagini Myers JM, Mukkada VA, Putnam PE, Khurana Hershey GK, Kottyan LC, Wen T, Martin LJ, Rothen-
berg ME. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses. Sci Transl Med
2018;10:eaap9736.
36. Anthiya S, Griveau A, Loussouarn C, Baril P, Garnett M, Issartel JP, Garcion E. MicroRNA-based drugs for brain tumors. Trends Cancer
2018;4:222-38.
37. Guo J, Jiang X, Gui S. RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine 2016;11:5287-
310.
38. Aceves SS. Unmet therapeutic needs in eosinophilic esophagitis. Dig Dis 2014;32:143-8.
39. Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, Schorl C, Brodsky AS, Resnick MB. MicroRNA profiling in mucosal biop-
sies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets. PLoS One 2012;7:e40676.
40. Kelbel TE, Ghaffari G, Sena M, Ishmael FT. Salivary microRNA as a biomarker for monitoring response to treatment in eosinophilic esoph-
agitis. J Allergy Clin Immunol 2015;135:AB78.
41. Swanson K, Devaraj, S., Shulman, R., Schaefer, J., Hiremath, G. . Salivary microRNAs in eosinophilic esophagitis: pathobiologic implica-
tions and potential as noninvasive biomarker. Gastroenterology 2016;150:S673-S4.
42. Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, Caldwell JM, Capocelli KE, Carpenter CL, Collins MH, Dellon ES, Eby MD,
Gonsalves N, Gupta SK, Falk GW, Hirano I, Menard-Katcher P, Kuhl JT, Krischer JP, Leung J, Mukkada VA, Spergel JM, Trimarchi MP,
Yang GY, Zimmermann N, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Eo-
sinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastro-
enterol Hepatol 2018;3:477-88.